证券代码：688566 证券简称：吉贝尔 公告编号：2024-061 公司与深圳华大海洋科技有限公司（以下简称"华大海洋"，为标的公司控 股股东）因深圳华泓海洋生物医药有限公司（以下简称"华泓生物"，为标的公 司）股权回购产生纠纷，公司向上海国际经济贸易仲裁委员会（上海国际仲裁中 心）提起仲裁，并于近日收到上述案件的《受理通知》（上国仲（2024）第 3816 号）。截至本公告披露日，该案件已获受理，尚未开庭审理。 （一）仲裁当事人 申请人：江苏吉贝尔药业股份有限公司 1 案件所处的仲裁阶段：案件已受理，尚未开庭审理 公司所处的当事人地位：江苏吉贝尔药业股份有限公司（以下简称"公 司"）为仲裁申请人 涉案的金额：1、裁决被申请人履行回购股权义务，支付申请人投资款 60,000,000 元；2、裁决被申请人支付违约金 12,000,000 元；合计： 72,000,000 元。 对公司的影响：该仲裁案件不影响公司日常生产经营。鉴于上述案件尚 未审理，对公司的影响具有不确定性，最终实际影响以仲裁结果及最终 执行等为准。为维护公司及股东的合法权益，公司高度重视并密切关注 上述案件的进展，将根据有关规定及时履行信息披 ...

关于江苏吉贝尔药业股份有限公司 以简易程序向特定对象发行股票限售股上市流通的 核查意见 国金证券股份有限公司（以下简称"国金证券""保荐机构"）作为江苏吉贝 尔药业股份有限公司（以下简称"吉贝尔""公司"）的持续督导机构，根据《中 华人民共和国公司法》《中华人民共和国证券法》《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等有关法律法规和规范性文件的要 求，对吉贝尔以简易程序向特定对象发行股票限售股上市流通事项进行了核查， 核查情况及核查意见如下： 一、本次上市流通的限售股类型 2024 年 6 月 5 日，吉贝尔收到中国证券监督管理委员会出具的《关于同意 江苏吉贝尔药业股份有限公司向特定对象发行股票注册的批复》（证监许可〔2024〕 843 号），同意公司以简易程序向特定对象发行股票（简称"本次发行"）的注册 申请。本次发行新增的 7,446,889 股股份已于 2024 年 6 月 21 日在中国证券登记 结算有限责任公司上海分公司办理完毕股份登记手续。 本次上市流通的限售股为公司以简易程序向特定对象发行的限售股份，限售 期为 6 个月，涉及 10 名认购对象，共计 7,446,88 ...

江苏吉贝尔药业股份有限公司 证券代码：688566 证券简称：吉贝尔 公告编号：2024-060 以简易程序向特定对象发行股票限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为向特定对象发行股份；股票认购方式为网下，上市股 数为 7,446,889 股。 本次股票上市流通总数为 7,446,889 股。 本次股票上市流通日期为 2024 年 12 月 23 日。 具体内容详见公司在上交所网站（www.sse.com.cn）披露的《江苏吉贝尔药业 股份有限公司关于 2021 年限制性股票激励计划第三个归属期归属结果暨股票上市 公告》（公告编号：2024-052）。 除上述情况外，本次上市流通的限售股形成后至本公告披露日，公司股本数量 未发生其他变化。 一、本次上市流通的限售股类型 2024 年 6 月 5 日，江苏吉贝尔药业股份有限公司（以下简称"公司"）收到 中国证券监督管理委员会（以下简称"中国证监会"）出具的《关于同意江苏吉贝 尔药业股份有限公司向特定对象发行股票注册 ...

Group 1: Company Overview and Financial Performance - The company, Jiangsu Jibeier Pharmaceutical Co., Ltd., reported a revenue of 643.21 million yuan for the first three quarters of 2024, representing a year-on-year growth of 4.25% [4] - The net profit attributable to shareholders for the same period was 174.56 million yuan, showing a year-on-year increase of 12.57% [4] - R&D investment for the first three quarters of 2024 was 51.89 million yuan, accounting for 23.25% of the company's revenue [10] Group 2: Product Highlights and Market Potential - The main product, Nigulol Tablets, is expected to reach annual sales of a certain volume when the market saturation is achieved, with significant application prospects in treating hypertension with high heart rates [4] - Research indicates that over one-third of hypertension patients also experience rapid heart rates, highlighting the market potential for Nigulol Tablets [4] - The product is included in several national medical guidelines, indicating its recognized therapeutic value [4] Group 3: Future Developments and Innovations - The company is advancing the clinical trials for the new antidepressant drug JJH201501, which is currently in Phase III trials [4] - JJH201601, an anti-tumor drug, has received approval for clinical trials and is progressing through various phases of testing [8] - The company is focusing on innovation and R&D, with plans to increase R&D investment as new drug development progresses [10] Group 4: Shareholder Engagement and Dividend Policy - The company has implemented a profit distribution plan for the first three quarters of 2024, with a focus on maintaining a stable dividend policy to reward shareholders [6] - The management is committed to enhancing shareholder value through sustainable growth and regular dividends [6] - The company is actively monitoring its stock price and is focused on long-term development and innovation to improve its competitive position [6]

证券代码：688566 证券简称：吉贝尔 公告编号：2024-059 江苏吉贝尔药业股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议线上交流时间：2024 年 11 月 26 日（星期二）下午 15:00-16:00 会议召开方式：线上文字互动 线 上 文 字 互 动 平 台 ： 东 方 财 富 路 演 平 台 （ 网址： http://roadshow.eastmoney.com/luyan/4580568） 投资者可于 2024 年 11 月 25 日（星期一）16:00 前通过邮件、电话等形式 将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者普 遍关注的问题进行回答。 江苏吉贝尔药业股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日在上海证券交易所网站（www.sse.com.cn）发布《公司 2024年第三季度报告》， 为便于广大投资者更全面深入地了解公司 2024 年第三季度经营成果、财务状况、 ...

Group 1: Industry Overview - The innovative drug industry is experiencing rapid growth due to policy support, market recognition, and increasing demand [1][5] - The National Medical Products Administration announced a notification to expedite the approval process for innovative drugs starting November 1, 2024, which is expected to shorten the time to market for eligible drugs [1][5] - Recent reforms in the healthcare system aim to support high-quality development of pharmaceutical innovation, with multiple measures introduced at both national and local levels [5] Group 2: Company Performance - Jibeier (688566) reported a revenue of 643 million yuan for the first three quarters, a year-on-year increase of 4.25%, and a net profit of 175 million yuan, up 12.57% [1][2] - The company has formed a research and development team of over 100 professionals and established a new drug R&D technology platform focusing on various innovative drug technologies [2] Group 3: Research and Development Pipeline - Jibeier is developing several innovative drugs, including JJH201501 (an antidepressant), JJH201601 (an anti-tumor drug), JJH201701 (an anti-acid drug), JJH201801 (a treatment for gallbladder inflammation and gallstones), and JJH202301 (a hypoglycemic drug) [2][3] - JJH201501 is currently undergoing Phase III clinical trials, showing promising results in extending the drug's half-life and improving blood concentration [2] - JJH201601 has demonstrated significant anti-tumor effects in animal models and is currently in Phase I clinical trials [3] Group 4: Intellectual Property and Competitive Advantage - Jibeier has established multiple technical barriers to protect its flagship product, Likujun tablets, through patents and quality improvements, ensuring product quality and efficacy [4] - The company is the only global producer of Likujun tablets and has participated in drafting national drug standards [4] Group 5: Future Strategy - Jibeier plans to enhance its product pipeline by focusing on major disease markets and leveraging a combination of independent R&D, external collaborations, acquisitions, and product licensing [4]

2024 年前三季度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688566 证券简称：吉贝尔 公告编号：2024-058 江苏吉贝尔药业股份有限公司 本次利润分配预案符合相关法律法规、规范性文件及《公司章程》等有关 规定，本次利润分配预案拟分配金额与本年度已分配金额合计未超过公司 2024 年前三季度归属于上市公司股东的净利润。本次利润分配预案属于公司 2023 年年度股东大会授权董事会决策的权限范围并在有效期内，本次利润分配预案 经公司董事会审议通过后，无需提交公司股东大会审议。 二、 分配方案 1. 发放年度：2024 年前三季度 2. 分派对象： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2024/11/14 | 2024/11/15 | 2024/11/15 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经江苏吉贝尔药业股份有限公司（以下简称"公司"）2024 年 5 月 20 日的 2023 ...

证券代码：688566 证券简称：吉贝尔 公告编号：2024-056 江苏吉贝尔药业股份有限公司 2024 年前三季度利润分配预案公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配预案内容 根据《江苏吉贝尔药业股份有限公司 2023 年年度报告》《江苏吉贝尔 药业股份有限公司 2024 年第三季度报告》，截至 2023 年 12 月 31 日，江苏 吉贝尔药业股份有限公司（以下简称"公司"）母公司累计未分配利润为人 民币 524,076,644.54 元（经信永中和会计师事务所（特殊普通合伙）审计）； 2024 年前三季度公司实现归属于上市公司股东的净利润为 174,563,672.90 元 （未经审计），截至 2024 年 9 月 30 日，公司合并资产负债表未分配利润为 人民币 662,319,981.57 元（未经审计）。公司拟以实施权益分派股权登记日 登记的总股本为基数分配利润。本次利润分配预案如下： 公司拟以实施权益分派股权登记日登记的总股本为基数，向全体股东每 10 股派发现金红利 ...

江苏吉贝尔药业股份有限公司独立董事 关于第四届董事会第十二次会议相关事项的 一、《公司 2024年前三季度利润分配预案》的独立意见 我们认为:公司本次利润分配预案符合公司经营发展实际及相关法律法规、 规范性文件及《公司章程》的有关规定,不存在侵害全体股东特别是中小股东利 益的情形，有利于公司实现持续稳定发展，同意本次利润分配预案。 二、《关于对外投资暨关联交易的议案》的独立意见 我们认为:公司本次对外投资暨关联交易事项,是基于公司发展战略及 业务需要，符合公司发展规划。本次交易定价遵循公平、合理的原则，经各 方协商确定,与共同参与投资的其他投资方认购价格相同,符合有关法律、 法规、规范性文件及公司内部控制制度等有关规定,不存在有失公允或损害 公司利益的情形,履行了必要的审批程序,符合有关法律法规及《公司章程》 等规定,公司独立董事同意本次对外投资暨关联交易事项。 (以下无正文,下接签署页。) 范 明 ^ ll h 陈留平 刘同君 独立意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板股票上市规则》 《江苏吉贝尔药业股份有限公司章程》等相关要求,作为江苏吉贝尔药业股份有 限公司(以下简称"公司")的独 ...

Financial Performance - The company's revenue for Q3 2024 was CNY 209,545,575.24, representing a year-on-year increase of 5.74%[2] - Net profit attributable to shareholders decreased by 10.62% year-on-year to CNY 52,557,701.84[2] - The basic earnings per share for Q3 2024 was CNY 0.27, down 12.90% from the same period last year[2] - Total operating revenue for the first three quarters of 2024 reached CNY 643,207,277.90, an increase of 4.0% compared to CNY 616,974,946.31 in the same period of 2023[15] - Operating profit for the first three quarters of 2024 was CNY 200,916,397.16, up 13.4% from CNY 177,119,692.84 in the previous year[16] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 174,563,672.90, representing a growth of 12.5% compared to CNY 155,068,445.62 in 2023[16] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 0.91, an increase from CNY 0.83 in the same period last year[18] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,491,846,662.37, reflecting a 12.77% increase from the end of the previous year[3] - The total assets of the company reached CNY 2,491,846,662.37, up from CNY 2,209,668,213.23, representing a growth of 12.7%[14] - The company's current assets totaled approximately RMB 1.32 billion, up from RMB 1.13 billion in the previous year, indicating a year-over-year increase of around 17%[12] - The total liabilities decreased to approximately RMB 1.32 billion from RMB 1.38 billion, indicating a reduction of about 4.3%[12] - Total liabilities decreased to CNY 230,792,139.31 from CNY 299,249,332.90, reflecting a reduction of approximately 22.9%[14] - The total equity attributable to shareholders increased by 18.42% year-on-year to CNY 2,255,725,339.58[3] - Total equity attributable to shareholders of the parent company increased to CNY 2,255,725,339.58, up from CNY 1,904,838,829.13, marking a growth of 18.4%[14] Cash Flow - Cash flow from operating activities for the year-to-date increased by 77.88%, primarily due to higher cash receipts from sales[6] - In the first three quarters of 2024, Jiangsu Jibeier Pharmaceutical Co., Ltd. reported cash inflows from operating activities of CNY 746,171,527.20, an increase of 29.8% compared to CNY 575,128,479.21 in the same period of 2023[19] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 169,962,425.71, up from CNY 95,548,318.75 in 2023, representing a growth of 77.6%[20] - Cash inflows from financing activities amounted to CNY 239,989,159.87 in the first three quarters of 2024, significantly higher than CNY 34,461,100.37 in the same period of 2023[21] - The net cash flow from financing activities improved to CNY 187,685,134.97 in 2024, compared to a negative CNY 10,804,883.63 in 2023[21] - The total cash and cash equivalents at the end of Q3 2024 stood at CNY 629,390,033.36, an increase from CNY 517,845,879.38 at the end of Q3 2023[21] Expenses - Research and development expenses totaled CNY 16,547,121.94, accounting for 7.90% of revenue, an increase of 1.09 percentage points compared to the same period last year[3] - Research and development expenses for the first three quarters of 2024 were CNY 31,163,217.53, down 26.0% from CNY 42,098,394.87 in the previous year[15] - Sales expenses increased to CNY 291,673,646.34, compared to CNY 280,725,066.96 in the same period of 2023, reflecting a rise of 3.4%[15] - The company reported a decrease in tax and surcharges to CNY 9,296,436.07 from CNY 7,269,068.80, indicating an increase of 28.0%[15] - The cash paid to employees and for employee benefits increased to CNY 174,344,919.66 in 2024, compared to CNY 161,058,884.67 in 2023, reflecting a rise of 8.0%[20] - The company’s cash outflows for taxes paid rose to CNY 95,089,353.44 in 2024, up from CNY 70,231,923.29 in 2023, marking an increase of 35.4%[20] Shareholder Information - The top ten shareholders held a combined 70.80% of the company's shares, with the largest shareholder owning 27.28%[8] - The company has not reported any significant changes in shareholder financing or stock lending activities during the reporting period[10] Strategic Developments - There are no new strategies or major product developments mentioned in the report for the upcoming quarters[10] - Jiangsu Jibeier Pharmaceutical Co., Ltd. has not adopted new accounting standards for the year 2024, as indicated in their report[22] Other Financial Metrics - The weighted average return on equity decreased by 0.89 percentage points to 2.39%[2] - The company reported non-recurring gains of CNY 1,689,064.39 for the current period[5] - Cash and cash equivalents decreased to approximately RMB 630 million from RMB 694 million, reflecting a decline of about 9%[11] - Trade receivables increased to approximately RMB 259.69 million, compared to RMB 228.85 million, marking an increase of about 13%[11] - Inventory rose to approximately RMB 34.72 million from RMB 29.51 million, which is an increase of about 17%[12] - The company's long-term equity investments slightly decreased to approximately RMB 122.85 million from RMB 126.19 million, a decline of about 2.6%[12] - The company reported a significant increase in trading financial assets, which rose to RMB 331 million from RMB 35 million, representing a growth of approximately 846%[11]